ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

ADCT ADC Therapeutics SA

4.46
0.02 (0.45%)
2024年4月27日 - 終了
15分遅延
名称 銘柄コード 市場 種別
ADC Therapeutics SA ADCT NYSE 普通株式
  前日比 前日比 % 現在値 時刻
0.02 0.45% 4.46 08:51:24
始値 安値 高値 終値 前日終値
4.44 4.21 4.51 4.34 4.44
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/0420:00GLOBEADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial..
2024/4/0320:00GLOBEADC Therapeutics to Host a Virtual Research Investor Event..
2024/4/0205:05GLOBEADC Therapeutics Makes Grants to New Employees Under..
2024/3/1320:03IHMARKETNEWSMixed Futures Amidst Quiet Economic Schedule; Oil Prices..
2024/3/1320:00GLOBEADC Therapeutics Reports Fourth Quarter and Full Year 2023..
2024/3/0621:15GLOBEADC Therapeutics to Participate in the Guggenheim 5th Annual..
2024/3/0621:00GLOBEADC Therapeutics to Host Fourth Quarter and Year-End 2023..
2024/3/0607:45GLOBEADC Therapeutics Announces Abstracts Accepted for..
2024/3/0523:15EDGAR2Form 8-K - Current report
2024/3/0106:30EDGAR2Form 8-K - Current report
2024/2/2721:00GLOBEADC Therapeutics to Participate in the TD Cowen 44th Annual..
2024/1/2422:00EDGAR2Form 8-K - Current report
2024/1/2006:30EDGAR2Form 8-K - Current report
2024/1/0421:15EDGAR2Form 8-K - Current report
2024/1/0421:15GLOBEADC Therapeutics Regains Compliance with NYSE Continued..
2024/1/0421:00EDGAR2Form 8-K - Current report
2024/1/0421:00GLOBEADC Therapeutics Provides Business Updates
2024/1/0310:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
2024/1/0310:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
2024/1/0310:04EDGAR2Form 3 - Initial statement of beneficial ownership of..
2024/1/0310:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
2024/1/0309:59EDGAR2Form 3 - Initial statement of beneficial ownership of..
2024/1/0309:58EDGAR2Form 3 - Initial statement of beneficial ownership of..
2023/12/1921:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/1906:25EDGAR2Form S-8 - Securities to be offered to employees in employee..
2023/12/1219:15GLOBEADC Therapeutics Announces Initial Results from..
2023/12/0506:57EDGAR2Form S-8 - Securities to be offered to employees in employee..
2023/11/2016:40PRNUSSobi to present new data at ASH 2023 Annual Meeting
2023/11/1517:00GLOBEMyricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur..
2023/11/0721:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/0721:15GLOBEADC Therapeutics Receives NYSE Notice of Non-Compliance With..
2023/11/0721:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/0721:00GLOBEADC Therapeutics Reports Third Quarter 2023 Financial..
2023/11/0621:00GLOBEADC Therapeutics to Participate in the Jefferies London..
2023/11/0223:10GLOBEADC Therapeutics Announces Abstracts Accepted for..
2023/10/2420:00GLOBEADC Therapeutics to Host Third Quarter 2023 Financial..
2023/10/0417:00GLOBEMyricx Expands its ADC Expertise with the Appointment of..
2023/9/1120:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/9/0520:00GLOBEADC Therapeutics to Participate in September Investor..
2023/8/3108:32GLOBEADC Therapeutics Announces Updates on ZYNLONTA® LOTIS..
2023/8/0820:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/8/0820:00GLOBEADC Therapeutics Reports Second Quarter 2023 Financial..
2023/8/0120:00GLOBEADC Therapeutics to Host Second Quarter 2023 Financial..
2023/7/2420:21GLOBEOverland ADCT BioPharma Announces NMPA Accepts Biologics..
2023/7/2105:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/7/2105:05GLOBEADC Therapeutics Announces Plan to Discontinue the Phase 2..
2023/7/1122:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/7/1120:00GLOBEADC Therapeutics Announces Voluntary Pause of Enrollment in..
2023/6/1520:15GLOBEADC Therapeutics Announces Evolution of Board of Directors
2023/6/0920:15GLOBEADC Therapeutics Announces Updated LOTIS-2 Results..

最近閲覧した銘柄

Delayed Upgrade Clock